What question did this study set out to answer?

This study aims to evaluate the safety and efficacy of finerenone for treating primary aldosteronism.

January 10, 2026Diabetes & Metabolic Syndrome Clinical Research & Reviews0 citations

Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study

SLShuo LiTianjin Medical University General Hospital YZY ZhangTianjin Medical University General Hospital XLXuan LiuTianjin Medical University General Hospital

Key Result

Finerenone improved serum potassium levels to normal in 47% of primary aldosteronism patients without potassium supplementation at 4 weeks.

Key Points

This study aims to evaluate the safety and efficacy of finerenone for treating primary aldosteronism.
Enrolled 15 patients diagnosed with primary aldosteronism.
Measured serum potassium levels without supplementation after 4 weeks.
Monitored changes in systolic blood pressure, diastolic blood pressure, and renal function.
Assessed the incidence of hyperkalemia during follow-ups.
47% of patients achieved normal serum potassium without supplementation at 4 weeks.
Serum potassium levels significantly increased at 2, 4, and 8 weeks post-treatment.
Systolic blood pressure significantly decreased at both the 4-week and 8-week follow-ups.
Changes in serum creatinine and estimated glomerular filtration rate were noted, especially in patients with chronic kidney disease, but were not statistically significant.
No cases of hyperkalemia or unexpected safety issues occurred.

Structured PICO

Does finerenone improve serum potassium levels and blood pressure in patients with primary aldosteronism?

Population

15 patients with primary aldosteronism (PA) and baseline hypokalemia (serum potassium <3.5 mmol/L)

Intervention

Finerenone

Outcome

Proportion of patients achieving normal serum potassium levels without potassium supplementation at the 4-week follow-upsurrogate

Finerenone effectively corrects hypokalemia and reduces systolic blood pressure in patients with primary aldosteronism, suggesting it as a promising targeted treatment option.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

AIMS: This study aimed to evaluate the safety and efficacy of finerenone in the treatment of primary aldosteronism (PA). METHODS: A total of 15 patients with PA were enrolled. The primary endpoint was the proportion of patients achieving normal serum potassium levels without potassium supplementation at the 4-week (4W) follow-up. Secondary endpoints included changes in serum potassium, 24-h urinary potassium, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Serum creatinine, estimated glomerular filtration rate (eGFR), and hyperkalemia incidence were also assessed during follow-ups. RESULTS: At baseline, all patients had hypokalemia (serum potassium <3.5 mmol/L). At 4W, 47 % (7/15) of patients achieved normal serum potassium without supplementation. Serum potassium levels significantly increased at the 2W, 4W, and 8W follow-ups compared to baseline (all p < 0.05). SBP significantly decreased at the 4W and 8W follow-ups (all p < 0.05), while DBP showed no significant changes. Increases in serum creatinine and decreases in eGFR were observed, particularly in patients with PA and chronic kidney disease (CKD), although these changes were not statistically significant. No instances of hyperkalemia or unexpected safety concerns were reported. CONCLUSION: Finerenone effectively increased serum potassium levels and reduced SBP in PA, demonstrating its potential as a promising treatment option.

Ask AI

Helpful

Bookmark

View Full Paper